15 Mar 2007 - Pacgen Biopharmaceuticals Corporation announced the appointment of Robert 'Duffy' DuFresne as President and Chief Executive Officer. Mr. DuFresne replaces Dr. David Cheng who held the position since he co-founded the company in 2004. Dr. Cheng will continue to lead scientific affairs at Pacgen as Chief Scientific Officer and also as a Director. Mr. DuFresne will also be joining the Board as a Director.
Mr. DuFresne was President and CEO of Zelos Therapeutics Inc, and prior to that President and CEO ConjuChem Inc. He has over 25 years of experience in the biotechnology, pharmaceutical and medical device industries. His background includes functional responsibilities in the areas of business development, finance, and general management. Mr. DuFresne also held the positions of President and COO at Anika Therapeutics and Senior Vice President, Marketing and Business Development at Alpha-Beta Technology. Mr. DuFresne's pharmaceutical industry experience includes senior management positions at the Canadian subsidiary of Boots Pharmaceutical, and at Baxter International. Mr. DuFresne received his B.A. and M.B.A. from Harvard University.
 |
www.bionity.com/news/e/62750 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/62750 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |